Bachem Holding AG
Bachem Holding AG (BANB.SW) Stock Overview
Explore Bachem Holding AG’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4.3B
P/E Ratio
35.82
EPS (TTM)
$1.60
ROE
0.09%
BANB.SW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bachem Holding AG (BANB.SW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 55.25, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $65.10.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 35.82 and a market capitalization of 4.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Thomas Meier
2,207
Hauptstrasse 144, Bubendorf
1998